EU Green light for Ocrevus in primary progressive MS

12 January 2018
2019_biotech_test_vial_discovery_big

Today, Ocrevus (ocrelizumab) was granted a licence by the European Commission to treat people with two forms of multiple sclerosis (MS) including the first and only licence for primary progressive MS (PPMS), the most debilitating form of the disease, in which disability increases from the outset.

Ocrevus, from Switzerland’s Roche (ROG: SIX), best known as the world’s largest cancer drugs maker, has also been licensed for relapsing MS (RMS), providing a new treatment option for these patients. The full approval comes after a positive opinion last November from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Roche’s shares were up 1% at 246.95 Swiss francs in early trading this morning.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology